10 Best Income Stocks to Invest in Now

2. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 98

Johnson & Johnson (NYSE:JNJ) is a leading US-based multinational focused on pharmaceuticals, biotech, and medical technology. The company reported solid first-quarter 2025 results. Revenue reached $21.9 billion, up 2.4% from the same period last year and beating expectations by $315.6 million. Net income surged to $11 billion, marking a year-over-year increase of 238%.

Johnson & Johnson (NYSE:JNJ) made notable strides in innovation during the quarter, pushing forward key pipeline projects such as TREMFYA for inflammatory bowel disease, a drug combination involving RYBREVANT and LAZCLUZE for treating non-small-cell lung cancer, and progress with OTTAVA, its robotic surgery platform. It also broadened its neuroscience capabilities through the acquisition of Intra-Cellular Therapies.

From a dividend point of view, Johnson & Johnson (NYSE:JNJ) remained financially strong, generating $3.4 billion in free cash flow, up from $2.8 billion the year before. On April 15, the company raised its quarterly dividend by 4.8% to $1.30 per share, marking its 63rd straight year of dividend growth. The stock supports a dividend yield of 3.37%, as of May 9.